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Background:  Individual platelet response to antiplatelet therapy depends on genetic, cellular and clinical factors. CYP2C19 and P2Y12 
receptor polymorphisms are implicated in platelet response to antiplatelet treatment. We evaluated the impact of CYP2C19 and C34T 
P2Y12 genotyping on platelet reactivity and cardiovascular outcome in patients after percutaneous coronary intervention (PCI) receiving 
clopidogrel treatment.
methods:  We enrolled 408 patients with stable coronary artery disease (CAD) receiving aspirin and clopidogrel (75mg/d), one month after 
PCI. High on treatment platelet reactivity was evaluated using VerifyNow Assay. VerifyNow reports its results in P2Y12 reaction units (PRU) 
and the diagnostic cut-off value is 230 PRU. CYP2C19*2 and C34T P2Y12 genotyping was performed by real-time polymerase chain 
reaction. The primary end point was the composite of death or hospitalization for cardiovascular causes and patients were followed for a 
mean time of 14 months.
results:  In the total study population, 37% were carriers of at least one CYP2C19*2 reduced-function allele and 53% were carriers of 
at least one C34T reduced-function allele. Interestingly, carriers of two CYP2C19*2 reduced-function allele had significantly increased 
PRU (292±53 vs. 198±83, p=0.007). On the contrary, PRU did not differ between carriers and non-carriers of the C34T-allele (199±91 
vs. 208±80, p=0.41). Moreover, although the rate of occurrence of primary end point differ significantly between carriers and non carriers 
of CYP2C19*2 (for carriers HR=1.96, 95%C.I. 1.05 to 3.66, p=0.03), C34T polymorphism had no impact on cardiovascular outcome (for 
carriers HR: 1.61, 95%CI 0.82 to 3.18, p=0.17).
Conclusion:  We documented a different effect of CYP2C19 and P2Y12 receptor polymorphisms, on platelet reactivity and cardiovascular 
outcome in CAD patients after PCI receiving clopidogrel treatment.
